(-)-MK 801 Maleate - CAS 121917-57-5
Not Intended for Therapeutic Use. For research use only.
Product Name:
(-)-MK 801 Maleate
Catalog Number:
CAS Number:
MK-801 is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
Molecular Weight:
Molecular Formula:
NMDA Receptor
Chemical Structure
CAS 121917-57-5 (-)-MK 801 Maleate

Related NMDA Receptor Products

CAS 121917-57-5 (-)-MK 801 Maleate

(-)-MK 801 Maleate
(CAS: 121917-57-5)

MK-801 is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.

(CAS: 1237744-13-6)

QNZ46, a NMDA receptor antagonist, has been studied to have potential effect in some neurological diseases for it works by influencing some amino acids combinat...

(CAS: 117928-94-6)

Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepres...

Dioxadrol hydrochloride
(CAS: 631-06-1)

Dioxadrol hydrochloride has been found to be an NMDA antagonist and is used as a dissociative anaesthetic drug. It produces similar effects to PCP in animals. I...

(CAS: 199467-52-2)

AM-36 is a potent blocker of batrachotoxinin (BTX)-sensitive Na+ channel binding in rat brain homogenates with an IC50 of 0.28 microM. As a unique neuroprotecti...

CAS 169274-78-6 Ro 25-6981

Ro 25-6981
(CAS: 169274-78-6)

Ro 25-6981, structurally related to ifenprodil and with no affinity for the known binding sites of non-competitive antagonists such as phencyclidine or MK-801, ...

Cgp 31358
(CAS: 125652-47-3)

CGP 31358 is a compound that can bind to a site on the N-methyl-D-aspartate (NMDA) receptor which is coupled to both the transmitter recognition site and the ch...

CAS 127910-32-1 CGP 39551

CGP 39551
(CAS: 127910-32-1)

Cgp 39551 is a selective and competitive N-methyl-D-aspartate (NMDA) receptor antagonist originated by Novartis. Ki is 310 nM for inhibition of [3H]-CPP binding...

(CAS: 459836-30-7)

PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC50=270 nM), rather than 1A/...

LY 257883
(CAS: 118183-22-5)

LY 257883, also known as PPPA, is a competitive NMDA receptor antagonist which displays moderate selectivity for NR2A-containing receptors. Ki values are 0.13μM...

CAS 4682-36-4 Orphenadrine Citrate

Orphenadrine Citrate
(CAS: 4682-36-4)

Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.

CAS 59-47-2 Mephenesin

(CAS: 59-47-2)

Mephenesin is an NMDA receptor antagonist, is a centrally acting muscle relaxant.

MDL 105519
(CAS: 161230-88-2)

MDL 105519, a ligand selective for the glycine binding site of NMDA receptor, was shown that completely inhibited the binding of [3H]glycine to rat brain membra...

Felbamate hydrate
(CAS: 1177501-39-1)

The hydrate of Felbamate which is an effective anticonvulsant agent. It was found to be clinically active for probably restraining the effectivity of NMDA.

Ro 25-6981 Maleate
(CAS: 1312991-76-6)

The Maleate salt form of Ro 25-6981 which is a NMDA receptors blocker and has been found to exhibit neuroprotectant activity in vitro and in vivo. IC50: 9 nM.

CAS 6384-92-5 NMDA

(CAS: 6384-92-5)

NMDA is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Unlike glutamate, NM...

CGP 43487
(CAS: 146388-56-9)

CGP 43487 has been found to be a NMDA receptor antagonist and was once studied about its influenment of dopaminergic function as a supplement in the treatment o...

(CAS: 853400-76-7)

Trofinetide is a NMDA antagonist under the development of Neuren Pharmaceuticals. It is an analogue of the neuropeptide (1-3) IGF-1, which is a simple tripeptid...

(CAS: 866927-10-8)

IC87201, an efficient inhibitor of PSD95-nNOS protein-protein interactions, was found by screening and shown to disrupt the nNOS/PSD-95 interaction in an in vit...

CAS 130798-51-5 MDL 29951

MDL 29951
(CAS: 130798-51-5)

Reference Reading

1.Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells.
Malsy M1, Gebhardt K2, Gruber M3, Wiese C4, Graf B5, Bundscherer A6. BMC Anesthesiol. 2015 Jul 29;15:111. doi: 10.1186/s12871-015-0076-y.
BACKGROUND: Adenocarcinoma of the pancreas is one of the most aggressive cancer diseases affecting the human body. The oncogenic potential of this type of cancer is mainly characterized by its extreme growth rate triggered by the activation of signaling cascades. Modern oncological treatment strategies aim at efficiently modulating specific signaling and transcriptional pathways. Recently, anti-tumoral potential has been proven for several substances that are not primarily used in cancer treatment. In some tumor entities, for example, administration of glutamate antagonists inhibits cell proliferation, cell cycle arrest, and finally cell death. To attain endogenic proof of NMDA receptor type expression in the pancreatic cancer cell lines PaTu8988t and Panc-1 and to investigate the impact of ketamine, s-ketamine, and the NMDA receptor antagonist MK 801 on proliferation, apoptosis, and necrosis in pancreatic carcinoma.
2.Evaluation of the role of N-methyl-D-aspartate (NMDA) receptors in insulin secreting beta-cells.
Patterson S1, Irwin N2, Guo-Parke H1, Moffett RC1, Scullion SM1, Flatt PR1, McClenaghan NH1. Eur J Pharmacol. 2016 Jan 15;771:107-13. doi: 10.1016/j.ejphar.2015.12.015. Epub 2015 Dec 10.
The possibility that antagonism of N-methyl-D-aspartate (NMDA) receptors represent a novel drug target for diabetes prompted the current studies probing NMDA receptor function in the detrimental actions of homocysteine on pancreatic beta-cell function. Cellular insulin content and release, changes in membrane potential and intracellular Ca(2+) and gene expression were assessed following acute (20min) and long-term (18h) exposure of pancreatic clonal BRIN-BD11 beta-cells to known NMDA receptor modulators in the absence and presence of cytotoxic concentrations of homocysteine. As expected, acute or long-term exposure to homocysteine significantly suppressed basal and secretagogue-induced insulin release. In addition, NMDA reduced glucose-stimulated insulin secretion (GSIS). Interestingly, the selective NMDA receptor antagonist, MK-801, had no negative effects on GSIS. The effects of the NMDA receptor modulators were largely independent of effects on membrane depolarisation and increases of intracellular Ca(2+).
3.Modulatory effects of inosine, guanosine and uridine on lipopolysaccharide-evoked increase in spike-wave discharge activity in Wistar Albino Glaxo/Rijswijk rats.
Kovács Z1, Kékesi KA2, Juhász G3, Dobolyi A4. Brain Res Bull. 2015 Sep;118:46-57. doi: 10.1016/j.brainresbull.2015.09.003. Epub 2015 Sep 10.
We showed previously that the number of spike-wave discharges (SWDs) was increased after intraperitoneal (i.p.) injection of lipopolysaccharide (LPS), inosine (Ino) and muscimol alone whereas i.p. guanosine (Guo), uridine (Urd), bicuculline, theophylline and (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine maleate (MK-801) alone decreased the SWD number in Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats. These drugs may exert their effects on absence epileptic activity mainly via proinflammatory cytokines-evoked increase in cortical excitability (such as LPS), GABAergic system (LPS, Ino, Urd, muscimol and bicuculline), glutamatergic system (LPS, Guo and MK-801) and adenosinergic system (LPS, Ino, Guo, Urd and theophylline). Both GABAergic system and glutamatergic system are involved in the pathomechanism of absence epilepsy, the LPS-evoked increase in absence epileptic activity and the pro- or antiepileptic effects of non-adenosine (non-Ado) nucleosides Ino, Guo and Urd.
4.Rewarding Effects of Optical Stimulation of Ventral Tegmental Area Glutamatergic Neurons.
Wang HL1, Qi J1, Zhang S1, Wang H1, Morales M2. J Neurosci. 2015 Dec 2;35(48):15948-54. doi: 10.1523/JNEUROSCI.3428-15.2015.
Ventral tegmental area (VTA) neurons play roles in reward and aversion. The VTA has three major neuronal phenotypes: dopaminergic, GABAergic, and glutamatergic. VTA glutamatergic neurons--expressing vesicular glutamate transporter-2 (VGluT2)--project to limbic and cortical regions, but also excite neighboring dopaminergic neurons. Here, we test whether local photoactivation of VTA VGluT2 neurons expressing Channelrhodopsin-2 (ChR2) under the VGluT2 promoter causes place preference and supports operant responding for the stimulation. By using a Cre-dependent viral vector, ChR2 (tethered to mCherry) was expressed in VTA glutamatergic neurons of VGluT2::Cre mice. The mCherry distribution was evaluated by immunolabeling. By confocal microscopy, we detected expression of mCherry in VTA cell bodies and local processes. In contrast, VGluT2 expression was restricted to varicosities, some of them coexpressing mCherry. By electron microscopy, we determined that mCherry-VGluT2 varicosities correspond to axon terminals, forming asymmetric synapses on neighboring dopaminergic neurons.